Colorectal Diagnostics

The stages and subtypes of colorectal cancer vary significantly in prognosis and treatment options, demonstrating a need for tools that assist pathologists in detecting and subtyping colorectal malignancies.

Ventana offers a comprehensive panel of ready-to-use rabbit and mouse colorectal assays, including IHC assays for the four most common mismatch repair (MMR) proteins, MLH-1 (M1) Mouse Monoclonal Primary Antibody, MSH2 (G219-1129), CONFIRM MSH6 (44) Mouse Monoclonal Primary Antibody and PMS2 (EPR3947), along with the BRAF V600E (VE1) Mouse Monoclonal Primary Antibody, for use on the fully-automated BenchMark series IHC/ISH platforms.

The VENTANA colorectal primary antibodies assist in diagnosis, risk stratification and subtyping while helping inform clinical decisions, and are supported by innovative automation, detection and workflow solutions.

 

VENTANA colorectal and gastrointestinal tools aid in diagnosis, subtyping and risk stratification with ready-to-use assays that include:

  • MMR protein and BRAF V600E (VE1) assays facilitate efficient and cost-effective subtyping within the anatomic pathology laboratory
  • Gastrointestinal IHC assays such as PATHWAY c-KIT (9.7) Primary Antibody and VENTANA Helicobacter pylori (SP48) Rabbit Monoclonal Primary Antibody
  • Highly sensitive and specific rabbit and mouse monoclonal assays

The VENTANA BRAF V600E (VE1) Mouse Monoclonal Primary Antibody is the only fully automated IHC test providing lab professionals and pathologists with a highly sensitive and specific, standardized testing method for the assessment of the BRAF V600E mutation in a variety of cancers.

Our BRAF V600E (VE1) assay demonstrates expected results on all VENTANA Benchmark IHC platforms with the OptiView DAB IHC Detection Kit, providing broad access and seamless integration into a laboratory’s workflow.

Virtual-slide-box-tour

Virtual Slide Box Tour

Click here to learn more

Print:

Related Links

 

Case Study

BRAF V600E IHC
Learn from Dr. Jayesh Desai, Royal Melbourne Hospital, on the importance of the BRAF V600E mutation and the value of BRAF V600E testing with immunohistochemistry.